Shilpa Gupta: NIAGARA trial insights on bladder cancer treatment
Shilpa Gupta shared a post by UroToday on X, adding the following:
“Had a great discussion on NIAGARA, the 1st ph 3 trial establishing improved OS & EFS with peri-operative chemo-IO in MIBC with the man, the myth, the legend Tom Powles.”
Quoting UroToday’s post:
“NIAGARA trial: Chemo + durvalumab improves survival in muscle-invasive Bladder Cancer.
Tom Powles, Barts Cancer Institute, joins Shilpa Gupta, Cleveland Clinic, to discuss the trial’s design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in event-free and overall survival. Full Video on UroToday.”
Dr. Shilpa Gupta is the Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.
For more posts featuring Shilpa Gupta, follow OncoDaily.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023